Joseph Rogers, DPM
Podiatrist · New Havent, CTNPI 1467783712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 32.3% of the total. Reporting peaked in 2022 at $319 and has fallen 91.3% since, to $28 in 2025.
Across 72 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$397
- Smith+Nephew$253
- Next Science LLC$79
- KCI USA, Inc.$57
- GRT US Holding, Inc.$50
- Merck$45
- plus $349 from 13 others
What the payments were for
- Food & beverage$1,230100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 31 | $397 |
| Smith+Nephew | 12 | $253 |
| Next Science LLC | 3 | $79 |
| KCI USA, Inc. | 3 | $57 |
| GRT US Holding, Inc. | 3 | $50 |
| Merck | 3 | $45 |
| Alfasigma USA, Inc. | 2 | $43 |
| Medtronic | 2 | $41 |
| Convatec Inc. | 2 | $34 |
| Reprise Biomedical, Inc. | 1 | $33 |
| Stryker | 1 | $31 |
| Averitas Pharma Inc. | 1 | $28 |
| DJO, LLC | 1 | $28 |
| Organogenesis Inc. | 2 | $26 |
| Amgen | 1 | $23 |
| Bioventus LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
How this compares
$1,230 in reported general payments places this provider in the 70th percentile of 119 podiatrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 44 | $1,014 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 11 | $733 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 16 | $328 |
| Clotrimazole | 15 | $207 |
| Ibuprofen | 15 | $144 |
| Mupirocin | 11 | $88 |
| Cephalexin | 14 | $60 |
| Meloxicam | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in New Havent
- Peter BlumeNew Haven$481K
- Robert DavisBridgeport$427K
- David NovickiMilford$67K
- Shane ReynoldsNorwalk$14K
- Eric LevineNorwich$12K
- Paul BetschartDanbury$10K
- Michael FeinBethel$9K
- Tehreem SajjadNew Britain$9K
- Christopher YardanWallingford$8K
- Jamie OtfinoskiBethel$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.